US20130039881A1 - Combination for the treatment of radiation- or chemotherapy-induced mucositis - Google Patents

Combination for the treatment of radiation- or chemotherapy-induced mucositis Download PDF

Info

Publication number: US20130039881A1
Authority: US; United States
Prior art keywords: treatment; oral; mucositis; pain; chemotherapy
Prior art date: 2009-11-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US13/511,900

Other languages

English (en)

Inventor

Franco Conti

Francesco Saverio Dioguardi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Professional Dietetics SpA

Original Assignee

Professional Dietetics SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-26

Filing date

2010-11-25

Publication date

2013-02-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42244328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130039881(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-25 Application filed by Professional Dietetics SpA filed Critical Professional Dietetics SpA

2012-06-28 Assigned to PROFESSIONAL DIETETICS S.R.L. reassignment PROFESSIONAL DIETETICS S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARBORIO MELLA (LEGAL REPRESENTATIVE AND HEIRESS OF DECEASED INVENTOR FRANCO CONTI), ISABELLA, CONTI (DECEASED), FRANCO, CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), EDOARDO CARLO MARIA, CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), GIOVANNI FEDERICO MARIA, DIOGUARDI, FRANCESCO SAVERIO

2013-02-14 Publication of US20130039881A1 publication Critical patent/US20130039881A1/en

Status Abandoned legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 17
206010028116 Mucosal inflammation Diseases 0.000 title claims abstract description 8
201000010927 Mucositis Diseases 0.000 title claims abstract description 8
238000001959 radiotherapy Methods 0.000 title abstract description 8
238000002512 chemotherapy Methods 0.000 title abstract description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims abstract description 18
239000004471 Glycine Substances 0.000 claims abstract description 11
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 10
229920000642 polymer Polymers 0.000 claims abstract description 10
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 9
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 9
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 9
239000004472 Lysine Substances 0.000 claims abstract description 9
230000005855 radiation Effects 0.000 claims abstract description 5
229920002674 hyaluronan Polymers 0.000 claims description 11
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 10
229960003160 hyaluronic acid Drugs 0.000 claims description 10
238000009472 formulation Methods 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 6
239000002324 mouth wash Substances 0.000 claims description 4
239000007921 spray Substances 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 3
239000000499 gel Substances 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
229940051866 mouthwash Drugs 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 8
208000002193 Pain Diseases 0.000 description 22
208000003265 stomatitis Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 6
230000009467 reduction Effects 0.000 description 5
230000036961 partial effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
231100000397 ulcer Toxicity 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
230000037319 collagen production Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
230000002265 prevention Effects 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
208000019505 Deglutition disease Diseases 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
238000001135 Friedman test Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
206010061336 Pelvic neoplasm Diseases 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229960003333 chlorhexidine gluconate Drugs 0.000 description 1
YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
ZCZQDTUCMRSEAS-CCLYOLAMSA-N co-codamol Chemical compound OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZCZQDTUCMRSEAS-CCLYOLAMSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000000315 cryotherapy Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000019564 dysgeusia Nutrition 0.000 description 1
230000000773 effect on pain Effects 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
206010030983 oral lichen planus Diseases 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000037390 scarring Effects 0.000 description 1
239000000779 smoke Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

the present invention relates to a combination of glycine, proline and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, for the treatment of mucositis induced by radiation or chemotherapy.
Oral mucositis is one of the most frequent and potentially serious side effects of non-surgical antitumoral treatment (1,2). Clinically, it is characterised by erythema, formation of ulcers with or without pseudo-membranes, bleeding, formation of exudates, and/or infections located at the upper level (3), and can evolve into a debilitating form which adversely affects the patient's quality of life.
the damage to the mucous membranes can extend from the oral cavity to the pharynx; in this invention, therefore, the term “oral mucositis” includes mucositis of the pharynx.
OM can be associated with pain symptoms such as dysgeusia, dysphagia, and difficulty in speaking, chewing or swallowing, with consequent impairment of the ability to eat, weight loss, and the need for feeding through a nasogastric tube.
the treatment of OM and the pain caused by it comprises: basic topical anaesthetics, systemic analgesics, anti-inflammatories, mucosa- coating agents, mouthwashes, oral hygiene in general, and antimicrobials (5,12-15).
basic topical anaesthetics systemic analgesics
anti-inflammatories e.g., aspirin, aspirin, aspirin, aspirin, and pulmonary embolism, and others.
mucosa- coating agents e.g., a number of other agents have also been tested, such as growth factors and cytokines, biological compounds that protect the mucosa, cryotherapy, and low-level laser treatment (13,16).
Hyaluronic acid plays an important role in tissue healing, by means of various mechanisms (17-19); clinical trials have also confirmed that it improves the healing process of ulcers of the lower limbs (20) and the nasal mucosa after surgery (21) and reduces acute epithelitis in patients who undergo radiotherapy to treat head, neck, breast or pelvic cancer (22).
the research therefore focuses on new treatment strategies for oral mucositis and the corresponding formulations.
WO 2007/048524 describes wound-healing pharmaceutical compositions comprising a combination of glycine, lysine, leucine and proline and sodium hyaluronan, which is particularly effective in facilitating the process of cell renewal that forms the basis of rapid wound-healing, promoting connective tissue reconstruction and consequent regeneration of the epithelial cells.
WO 2008/027904 discloses formulations of viscous polymers such hyaluronates or PVPs for treating stomatitis or mucositis.
WO 02/39978 discloses enteral nutritional supplement for malnourished or chronically ill patients comprising glutamine, anti-oxidants and fatty acids.
Glycine can be optionally present as a calcium antagonist.
combinations comprising glycine, proline, and optionally a natural or synthetic film-forming polymer, lysine and/or leucine, are effective in the treatment of oral mucositis induced by radiation or chemotherapy, especially as regards pain management.
the combination of glycine and proline surprisingly increases the gene expression of e-NO Synthase and of VEGF.
said aminoacids control and enhance the production of TGF beta and controls the collagen synthesis by fibroblasts quantitatively.
compositions according to the present invention have a considerable accelerating effect on wound-healing, and above all a surprising effect on pain management, especially in terms of pain reduction and immediate relief (only 2 hours after administration).
the use of the compositions according to the invention therefore constitutes a practical aid to pain management, providing rapid, effective pain reduction.
the present invention therefore relates to a formulation for oral use comprising:
the natural or synthetic film-forming polymer is selected from hyaluronic acid or a salt thereof, polyvinylpyrrolidone, and cellulose derivatives.
the natural or synthetic film-forming polymer is hyaluronic acid or a salt thereof.
aminoacids are present in the L form.
compositions according to the invention will contain the various active constituents in the following proportions of the composition by weight:
compositions according to the invention could be formulated suitably for topical administration in the form of a spray, aerosol, mouthwash or gel, and will be prepared according to conventional methods well known in pharmaceutical technology, such as those described in Remington's Pharmaceutical Handbook, Mack Publishing Co., New York, USA, using excipients, solubilisers, emollients, stabilisers, emulsifiers, pH regulators and preservatives acceptable for their final use.
the trial was conducted on 27 patients with OM, who had been treated recently (within two weeks) with daily doses of radiotherapy or chemotherapy, who presented at least grade 1 OM as assessed on the World Health Organisation (WHO) mucositis scale, and whose pain was not alleviated by treatment with paracetamol/co-codamol/acetylsalicylic acid.
Each patient was treated 3-4 times a day for 14 days with the composition according to the invention in spray form, which had to be maintained in situ for at least 2 minutes. They were instructed not to eat, drink or rinse their mouths for at least 1 hour.
Table I shows the pain score at the various assessment stages.
T0 baseline—before start of treatment
the following parameters were assessed: pain (using a linear visual analog scale from 1 to 100) and gravity of OM (using the WHO mucositis scale).
the efficacy of the treatment was assessed on the basis of the pain score, the clinical resolution index and patients' compliance at times T01 (after 2 hours), T1 (after 24 hours), T2 (after 72 hours), T3 (after 7 days) and T4 (after 14 days).
Intra-group test in repeated measures Intra-group models Mean test (Friedman Pain score (mm) ⁇ SD (Wilcoxon test) test) Pain T0 (baseline) 74.1 ( ⁇ 17.6) Significant (p ⁇ 0.0001) Pain T01 (after 2 h) 49.3 ( ⁇ 18.2) differences at Pain T1 (after 24 h) 39.4 ( ⁇ 22) T01 (p ⁇ 0.0001) Pain T2 (after 72 h) 24.8 ( ⁇ 19) and after 24 h, Pain T3 (after 7 days) 11.8 ( ⁇ 15.5) 72 h, 7 and 14 Pain T4 (after 14 days) 6.2 ( ⁇ 10.8) days (p ⁇ 0.0001) compared with baseline
Table II shows the effect of the treatment on the clinical resolution index.
the Friedman test showed a significant clinical improvement (p ⁇ 0.0001) compared with baseline at the various stages of measurement.
all patients showed a significant improvement compared with baseline (p ⁇ 0.0001), and their ability to swallow solids and liquids gradually improved.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)
Medicines Containing Plant Substances (AREA)

US13/511,900 2009-11-26 2010-11-25 Combination for the treatment of radiation- or chemotherapy-induced mucositis Abandoned US20130039881A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ITMI2009A002080		2009-11-26
ITMI2009A002080A IT1396935B1 (it)	2009-11-26	2009-11-26	Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
PCT/EP2010/068216 WO2011064297A1 (fr)	2009-11-26	2010-11-25	Combinaison pour le traitement d'une inflammation de muqueuse induite par rayonnement ou chimiothérapie

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/EP2010/068216 A-371-Of-International WO2011064297A1 (fr)	2009-11-26	2010-11-25	Combinaison pour le traitement d'une inflammation de muqueuse induite par rayonnement ou chimiothérapie

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US14/553,897 Continuation US9220726B2 (en)	2009-11-26	2014-11-25	Combination for the treatment of radiation- or chemotherapy-induced mucositis

Publications (1)

Publication Number	Publication Date
US20130039881A1 true US20130039881A1 (en)	2013-02-14

Family

ID=42244328

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US13/511,900 Abandoned US20130039881A1 (en)	2009-11-26	2010-11-25	Combination for the treatment of radiation- or chemotherapy-induced mucositis
US14/553,897 Active 2030-12-03 US9220726B2 (en)	2009-11-26	2014-11-25	Combination for the treatment of radiation- or chemotherapy-induced mucositis

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US14/553,897 Active 2030-12-03 US9220726B2 (en)	2009-11-26	2014-11-25	Combination for the treatment of radiation- or chemotherapy-induced mucositis

Country Status (19)

Country	Link
US (2)	US20130039881A1 (fr)
EP (1)	EP2504001B8 (fr)
JP (1)	JP2013512220A (fr)
KR (1)	KR101767226B1 (fr)
CN (1)	CN102655861A (fr)
BR (1)	BR112012012486A2 (fr)
CA (1)	CA2781820C (fr)
DK (1)	DK2504001T4 (fr)
ES (1)	ES2538349T5 (fr)
HR (1)	HRP20150523T1 (fr)
IT (1)	IT1396935B1 (fr)
NO (1)	NO2504001T3 (fr)
PL (1)	PL2504001T5 (fr)
PT (1)	PT2504001E (fr)
RS (1)	RS54014B1 (fr)
RU (1)	RU2570754C2 (fr)
SI (1)	SI2504001T1 (fr)
WO (1)	WO2011064297A1 (fr)
ZA (1)	ZA201203808B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20190017260A (ko)	2017-08-10	2019-02-20	주식회사 씨티에이	인터넷 플랫폼 기반을 이용한 bat제품 거래 방법
US20220233629A1 (en) *	2021-01-23	2022-07-28	Cellix Bio Private Limited	Composition comprising lidocaine, l-carnosine and dexpanthenol

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA030970B8 (ru)	2010-09-24	2019-01-31	Юниверсити Оф Флорида Рисёч Фаундейшн, Инк.	Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
ITMI20110954A1 (it) *	2011-05-26	2012-11-27	Professional Dietetics Srl	Combinazioni per il trattamento delle mucositi vaginali o rettali
FR2979241B1 (fr)	2011-08-30	2014-05-09	Nutrialys Medical Nutrition Sa	Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux
MX361647B (es)	2013-03-11	2018-12-13	Univ Florida	Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
ITMI20131660A1 (it)	2013-10-08	2015-04-09	Professional Dietetics Srl	Uso di una combinazione per la prevenzione delle mucositi indotte da radiazioni o da chemioterapici
EP3616689A1 (fr)	2014-11-24	2020-03-04	Entrinsic Health Solutions, Inc.	Compositions d'acides aminés pour le traitement de symptômes de maladies
KR102429451B1 (ko) *	2014-12-04	2022-08-04	프로페셔날 디에테틱스 에스.피.에이.	진피 연결 조직 중 섬유엘라스틴 회복을 위한 아미노산 기반의 조성물
MY187022A (en) *	2015-05-14	2021-08-26	Professional Dietetics Spa	Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
BR112019006742A2 (pt)	2016-10-04	2019-09-03	Entrinsic Health Solutions Inc	composições de aminoácido e usos das mesmas
RU2671512C1 (ru) *	2018-04-18	2018-11-01	федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России)	Средство для лечения заболеваний пародонта и слизистой оболочки рта с репаративным эффектом

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080261915A1 (en) *	2005-10-26	2008-10-23	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20090274660A1 (en) *	1999-08-17	2009-11-05	Immunopath Profile, Inc.	Pluripotent therapeutic compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5972884A (en)	1991-03-11	1999-10-26	Creative Biomolecules, Inc.	Morphogen treatment of gastrointestinal ulcers
DE10057290B4 (de) *	2000-11-17	2004-01-08	Fresenius Kabi Deutschland Gmbh	Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
US20050256042A1 (en)	2003-05-09	2005-11-17	Jeffers Michael E	Methods of preventing and treating alimentary mucositis
TW200536859A (en)	2004-01-27	2005-11-16	Nuvelo Inc	Gastrointestinal proliferative factor and uses thereof
GB0505975D0 (en)	2005-03-23	2005-04-27	Queen Mary & Westfield College	Novel use of peptide
ITMI20052036A1 (it)	2005-10-26	2007-04-27	Professional Dietetics Srl	Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
ITMI20052035A1 (it)	2005-10-26	2007-04-27	Professional Dietetics Srl	Composizioni farmaceutiche cicatrizzanti sotto forma di crema a base di amminoacidi e sodio ialuronato
EP2059206B8 (fr) *	2006-08-28	2012-07-11	Rexaderm, Inc.	Pansement de plaie sec et système de délivrance de médicament

2009
- 2009-11-26 IT ITMI2009A002080A patent/IT1396935B1/it active
2010
- 2010-11-25 DK DK10790906.1T patent/DK2504001T4/en active
- 2010-11-25 US US13/511,900 patent/US20130039881A1/en not_active Abandoned
- 2010-11-25 KR KR1020127013470A patent/KR101767226B1/ko active Active
- 2010-11-25 CA CA2781820A patent/CA2781820C/fr active Active
- 2010-11-25 PT PT107909061T patent/PT2504001E/pt unknown
- 2010-11-25 PL PL10790906T patent/PL2504001T5/pl unknown
- 2010-11-25 NO NO10790906A patent/NO2504001T3/no unknown
- 2010-11-25 JP JP2012540428A patent/JP2013512220A/ja not_active Withdrawn
- 2010-11-25 ES ES10790906.1T patent/ES2538349T5/es active Active
- 2010-11-25 SI SI201030933T patent/SI2504001T1/sl unknown
- 2010-11-25 RS RS20150354A patent/RS54014B1/sr unknown
- 2010-11-25 WO PCT/EP2010/068216 patent/WO2011064297A1/fr not_active Ceased
- 2010-11-25 BR BR112012012486A patent/BR112012012486A2/pt not_active Application Discontinuation
- 2010-11-25 CN CN2010800531477A patent/CN102655861A/zh active Pending
- 2010-11-25 RU RU2012121562/15A patent/RU2570754C2/ru active
- 2010-11-25 EP EP10790906.1A patent/EP2504001B8/fr active Active
- 2010-11-25 HR HRP20150523TT patent/HRP20150523T1/hr unknown
2012
- 2012-05-24 ZA ZA2012/03808A patent/ZA201203808B/en unknown
2014
- 2014-11-25 US US14/553,897 patent/US9220726B2/en active Active

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090274660A1 (en) *	1999-08-17	2009-11-05	Immunopath Profile, Inc.	Pluripotent therapeutic compositions and uses thereof
US20080261915A1 (en) *	2005-10-26	2008-10-23	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20190017260A (ko)	2017-08-10	2019-02-20	주식회사 씨티에이	인터넷 플랫폼 기반을 이용한 bat제품 거래 방법
US20220233629A1 (en) *	2021-01-23	2022-07-28	Cellix Bio Private Limited	Composition comprising lidocaine, l-carnosine and dexpanthenol
US11903992B2 (en) *	2021-01-23	2024-02-20	Cellix Bio Private Limited	Composition comprising lidocaine, l-carnosine and dexpanthenol

Also Published As

Publication number	Publication date
IT1396935B1 (it)	2012-12-20
EP2504001B1 (fr)	2015-03-04
ES2538349T3 (es)	2015-06-19
KR101767226B1 (ko)	2017-08-10
RS54014B1 (sr)	2015-10-30
DK2504001T4 (en)	2018-05-22
JP2013512220A (ja)	2013-04-11
ZA201203808B (en)	2013-08-28
US9220726B2 (en)	2015-12-29
RU2570754C2 (ru)	2015-12-10
ES2538349T5 (es)	2018-06-18
PL2504001T5 (pl)	2019-06-28
DK2504001T3 (en)	2015-05-11
US20150079009A1 (en)	2015-03-19
PL2504001T3 (pl)	2015-10-30
CA2781820A1 (fr)	2011-06-03
PT2504001E (pt)	2015-07-07
SI2504001T1 (sl)	2015-06-30
KR20120105454A (ko)	2012-09-25
WO2011064297A1 (fr)	2011-06-03
CN102655861A (zh)	2012-09-05
EP2504001B2 (fr)	2018-03-21
HRP20150523T1 (hr)	2015-06-05
ITMI20092080A1 (it)	2011-05-27
EP2504001B8 (fr)	2018-06-06
NO2504001T3 (fr)	2015-08-01
CA2781820C (fr)	2018-05-08
BR112012012486A2 (pt)	2016-04-12
RU2012121562A (ru)	2013-11-27
EP2504001A1 (fr)	2012-10-03

Publication	Publication Date	Title
US9220726B2 (en)	2015-12-29	Combination for the treatment of radiation- or chemotherapy-induced mucositis
US12485175B2 (en)	2025-12-02	Hypertonic antimicrobial therapeutic compositions
Colella et al.	2010	Efficacy of a spray compound containing a pool of collagen precursor synthetic amino acids (L-Proline, L-Leucine, L-Lysine and Glycine) combined with sodium hyaluronate to manage chemo/radiotherapy-induced oral mucositis: preliminary data of an open clinical trial
AU2014318702A1 (en)	2016-03-31	Hypertonic antimicrobial therapeutic compositions
US20200289413A1 (en)	2020-09-17	Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus
EP2859891B2 (fr)	2021-10-06	Utilisation d'une combinaison pour la prévention de la mucite induite par la radio ou la chimiothérapie
Schimmel et al.	2025	Integrating Oral Health in Palliative Medicine
Dios et al.	2020	Supportive and Palliative Care
Sourati et al.	2017	Oral Mucositis
POOL	0	Department of Head and Neck Surgery Second University of Naples, Naples; 1Department of Medical Oncology, University of Palermo, Palermo; 2Department of Oral Sciences, Unit of Oral Medicine, University of Palermo, Palermo, Italy
Aarti	2018	Comparision of Amnion Membrane and Hyaluronic Acid in Gingival Recession Coverage and Gain in Clinical Attachment Level Following Coronally Advanced Flap Procedure-a Clinical Study

Legal Events

Date	Code	Title	Description
2012-06-28	AS	Assignment	Owner name: PROFESSIONAL DIETETICS S.R.L., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONTI (DECEASED), FRANCO;CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), EDOARDO CARLO MARIA;CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), GIOVANNI FEDERICO MARIA;AND OTHERS;REEL/FRAME:028463/0776 Effective date: 20120605
2015-03-23	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

Date

Code

Title

Description

2012-06-28

Assignment

Owner name: PROFESSIONAL DIETETICS S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONTI (DECEASED), FRANCO;CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), EDOARDO CARLO MARIA;CONTI (LEGAL REPRESENTATIVE AND HEIR OF DECEASED INVENTOR FRANCO CONTI), GIOVANNI FEDERICO MARIA;AND OTHERS;REEL/FRAME:028463/0776

Effective date: 20120605

2015-03-23

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION